[Molecular-genetic determinants of the neoplastic process and state-of-the-art treatment of patients with uterine leiomyoma].
Present-day evidence on uterine leiomyomata has pointed to progesterone and its receptors as a key factor in the mechanisms of auto- and paracrine influences on tumor development and growth. Treatment was determined by a correlation between tumor size and stage of molecular-genetical disorders. A clinico-genealogical study of familial predisposition to uterine leiomyoma, particularly in patients from accumulated disease families contributed to the potential of early detection of tumor and timely effective correction for preservation of reproductive function.